Mr. Fust is an advisor on strategy and finance matters. Prior to advising Crinetics, Mr. Fust was chief financial officer and executive vice president at Onyx Pharmaceuticals, culminating in the company’s sale to Amgen. Prior to this role, he served as chief financial officer and senior vice president at Jazz Pharmaceuticals, chief financial officer at Perlegen Sciences, and chief financial officer and senior vice president at ALZA Corporation, where he was an executive through the company’s acquisition by Johnson & Johnson. Prior to these roles, he was a member of the healthcare strategy consulting practice at Andersen Consulting (now Accenture). He currently serves as an outside director of Atara, Dermira, MacroGenics, Sunesis, and Ultragenyx and is an advisor to several other life sciences executive teams and investors. He holds a B.A. in accounting from the University of Minnesota and M.B.A. from Stanford University.